-
Codon usage limitation in the expression of HIV-1 envelope glycoprotein.
Curr Biol. 1996 Mar 1;6(3):315-24
PMID: 8805248
-
CD21 augments antigen presentation in immune individuals.
Eur J Immunol. 1997 Jan;27(1):122-9
PMID: 9022008
-
HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity.
Virology. 1997 Mar 3;229(1):269-78
PMID: 9123870
-
Core structure of gp41 from the HIV envelope glycoprotein.
Cell. 1997 Apr 18;89(2):263-73
PMID: 9108481
-
Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer.
J Biol Chem. 2001 Oct 26;276(43):39577-85
PMID: 11514580
-
Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
J Virol. 2002 Mar;76(6):2835-47
PMID: 11861851
-
Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.
J Virol. 2002 May;76(9):4634-42
PMID: 11932429
-
Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
J Virol. 2002 Jun;76(11):5357-68
PMID: 11991964
-
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.
J Virol. 2002 Aug;76(15):7760-76
PMID: 12097589
-
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
J Virol. 2002 Sep;76(17):8875-89
PMID: 12163607
-
Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.
J Virol. 2003 Feb;77(3):2046-55
PMID: 12525639
-
Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.
Vaccine. 2003 Feb 14;21(9-10):902-14
PMID: 12547601
-
Impact of codon usage modification on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines.
Intervirology. 2002;45(4-6):275-86
PMID: 12566710
-
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
J Virol. 2003 Mar;77(5):3119-30
PMID: 12584337
-
HIV vaccine development: lessons from the past and promise for the future.
Curr HIV Res. 2003 Jan;1(1):101-20
PMID: 15043215
-
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes.
J Exp Med. 1988 Apr 1;167(4):1428-41
PMID: 3258626
-
Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes.
J Immunol. 1988 Jul 15;141(2):457-63
PMID: 2968402
-
The macrophage in the persistence and pathogenesis of HIV infection.
AIDS. 1989 Aug;3(8):475-95
PMID: 2508709
-
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.
Proc Natl Acad Sci U S A. 1990 Jan;87(2):648-52
PMID: 2300552
-
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Nature. 1990 Jun 14;345(6276):622-5
PMID: 2190095
-
Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.
J Virol. 1991 Jan;65(1):31-41
PMID: 1985202
-
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.
Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3097-101
PMID: 2014229
-
Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
AIDS Res Hum Retroviruses. 1991 Oct;7(10):791-8
PMID: 1742074
-
Induction of IFN-alpha in peripheral blood mononuclear cells by HIV-infected monocytes. Restricted antiviral activity of the HIV-induced IFN.
J Immunol. 1992 Jan 15;148(2):422-9
PMID: 1729362
-
Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein.
AIDS Res Hum Retroviruses. 1993 Jul;9(7):589-94
PMID: 8369163
-
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
J Virol. 1994 May;68(5):3015-26
PMID: 7512157
-
Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11699-703
PMID: 7972127
-
Co-ligation of mouse complement receptors 1 and 2 with surface IgM rescues splenic B cells and WEHI-231 cells from anti-surface IgM-induced apoptosis.
Eur J Immunol. 1995 Apr;25(4):1013-7
PMID: 7737272
-
The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity.
Annu Rev Immunol. 1995;13:127-49
PMID: 7542009
-
Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.
J Virol. 2000 May;74(10):4746-54
PMID: 10775613
-
Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein.
Virology. 1999 May 10;257(2):406-14
PMID: 10329551
-
Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins.
Clin Chem Lab Med. 1999 Mar;37(3):199-204
PMID: 10353461
-
Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
Vaccine. 1999 Apr 23;17(17):2166-75
PMID: 10367950
-
Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.
J Virol. 2000 Jun;74(12):5716-25
PMID: 10823881
-
A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
J Virol. 2000 Jan;74(2):627-43
PMID: 10623724
-
Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
J Virol. 2000 Mar;74(6):2628-35
PMID: 10684277
-
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
J Virol. 1997 Jun;71(6):4319-30
PMID: 9151820
-
Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
Virology. 1997 Apr 14;230(2):265-74
PMID: 9143282
-
Atomic structure of the ectodomain from HIV-1 gp41.
Nature. 1997 May 22;387(6631):426-30
PMID: 9163431
-
Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.
J Virol. 1997 Jul;71(7):5069-79
PMID: 9188572
-
Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain.
Structure. 1997 Jun 15;5(6):789-98
PMID: 9261070
-
The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2).
J Immunol. 1997 Oct 15;159(8):3782-91
PMID: 9378965
-
Atomic structure of a thermostable subdomain of HIV-1 gp41.
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12303-8
PMID: 9356444
-
Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage.
J Virol. 1998 Feb;72(2):1497-503
PMID: 9445053
-
DNA vaccines for immunodeficiency viruses.
AIDS. 1997;11 Suppl A:S109-19
PMID: 9451974
-
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
Science. 1998 Jun 19;280(5371):1884-8
PMID: 9632381
-
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.
J Virol. 1998 Sep;72(9):7620-5
PMID: 9696864
-
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.
J Virol. 1998 Nov;72(11):9092-100
PMID: 9765454
-
The complement system and adaptive immunity.
Semin Immunol. 1998 Oct;10(5):355-61
PMID: 9799710
-
DNA vaccines.
Dev Biol Stand. 1998;95:43-53
PMID: 9855413
-
DNA vaccines. Mechanisms for generation of immune responses.
Adv Exp Med Biol. 1998;452:187-91
PMID: 9889973
-
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.
J Virol. 1999 Mar;73(3):2343-9
PMID: 9971817
-
Cutting edge: recruitment of the CD19/CD21 coreceptor to B cell antigen receptor is required for antigen-mediated expression of Bcl-2 by resting and cycling hen egg lysozyme transgenic B cells.
J Immunol. 1999 Apr 15;162(8):4377-80
PMID: 10201971
-
DNA vaccines for viral infections: basic studies and applications.
Adv Virus Res. 2000;55:1-74
PMID: 11050940
-
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
J Virol. 2001 Jan;75(2):645-53
PMID: 11134278
-
Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.
J Virol. 2001 Feb;75(3):1165-71
PMID: 11152489
-
Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.
Infect Immun. 2001 May;69(5):3031-40
PMID: 11292721
-
C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.
Nat Immunol. 2000 Aug;1(2):127-31
PMID: 11248804
-
Stabilization of short collagen-like triple helices by protein engineering.
J Mol Biol. 2001 May 18;308(5):1081-9
PMID: 11352592
-
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
J Virol. 2001 Jun;75(12):5526-40
PMID: 11356960
-
Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.
AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):829-35
PMID: 11429124
-
C3d enhancement of neutralizing antibodies to measles hemagglutinin.
Vaccine. 2001 Oct 12;20(1-2):242-8
PMID: 11567770
-
Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
J Virol. 2001 Nov;75(22):10991-1001
PMID: 11602739
-
Candidate AIDS vaccines.
N Engl J Med. 1995 Nov 16;333(20):1331-9
PMID: 7566026
-
C3d of complement as a molecular adjuvant: bridging innate and acquired immunity.
Science. 1996 Jan 19;271(5247):348-50
PMID: 8553069
-
Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA.
Vaccine. 1995;13(15):1427-30
PMID: 8578820
-
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly.
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3099-104
PMID: 8610175
-
Particle-mediated nucleic acid immunization.
J Biotechnol. 1996 Jan 26;44(1-3):37-42
PMID: 8717384